Tag: ip1

JC: Thromboprophylaxis for the non ICU hospitalised COVID-19 patient. St Emlyn’s

Back in March we reported on a pre-print trial of thromboprophylaxis of ICU patients. The results suggested that there was no benefit for therapeutic dose anticoagulation in COVID19 as a prophylactic strategy for critically ill patients with COVID19. This

VITT

Post-vaccine headache in the Emergency Department: what you need to know. St Emlyn’s

I am sure you all saw the recent MHRA press release and guidance, discussing the issue of a possible link between the AstraZeneca COVID19 vaccine and a rare type of thrombotic condition of Vaccine induced

thromboprophylaxis

JC: Thromboprophylaxis on the ICU for COVID-19 patients. St Emlyn’s

The prevention of venous thromboembolism (VTE) has been a real concern in the management of hospitalised patients with COVID-19. We have previously discussed the role of prophylactic anticoagulation (thromboprophylaxis) for these patients as it was

February 2021 podcast

February 2021 Round Up Podcast. St Emlyn’s

Our regular podcast round up from February 2021. Iain and Simon highlight the key learning points from this month on the St Emlyn’s blog and podcast. Please remember to subscribe to the podcast on iTunes/Google

convalescent plasma

JC: Convalescent plasma (still) does not work in COVID-19. St Emlyn’s

The latest results on the use of convalescent plasma in Covid-19 are now out from the RECOVERY trial as a pre-print. As you know we have already covered the trial quite extensively and thus far

Colchicine

Colchicine does not improve mortality in COVID19. St Emlyn’s

This week the RECOVERY trial has released the first results from the Colchicine arm of the trial. We await the pre-print and the peer reviewed paper, but we are already very familiar with the trial

tocilizumab

Tocilizumabulous? A special offer on IL-6 with Tocilizumab.

It’s very rare we produce three instalments on one particular drug for one particular condition, and certainly not within such a short time frame. However, tocilizumab has been worth it. Maybe not the one intervention

tocilizumab

JC: RECOVERY trial shows Tocilizumab effective for COVID19. St Emlyn’s

In arguably the most important therapeutic news of the pandemic since Dexamethasone, the RECOVERY trial investigators have revealed the initial results on the Tocilizumab arm of the trial showing a significant benefit. This short blog

Tocilizumab

Tocilizumorelikeit? The latest data on Tocilizumab. St Emlyn’s

Hot on the heels of a terrific pun and blog post about the use of Tocilizumab, capturing all the intrigue, hope and caution with the potential use of this novel therapeutic agent for patients with severe

JC: Lopinavir/Ritonavir in the treatment of COVID-19

We have been following the RECOVERY trial closely over the last few months. It’s the largest RCT of therapeutics for COVID-19 in the world and it’s already shown that hydroxychloroquine and azithromycin don’t work in

MMU banner 1